Zacks Investment Research
03 Aug 2026, 18:31 UTC · 11w ago
Impact · against what's priced in
The medical sector faces a divergence between strong early reporting beats and a projected 15% aggregate earnings decline for the full quarter. While Amgen has a strong track record of beats, the broader sector's projected earnings contraction creates a headwinds environment for valuation.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Overall second-quarter earnings for the Medical sector are projected to fall by more than 15% year over year.
So whatA significant projected decline in aggregate sector earnings typically leads to downward pressure on valuations for the remaining companies in that sector.
More negative than 94% of claims this week
Early Q2 reports from the Medical sector have been stellar, with all participants outperforming on earnings and roughly 95% outperforming on revenues.
Continue reading
5 related stories
Amgen is highlighted for its impressive track record of beating earnings estimates over the last four quarters, providing positive momentum amid a mixed sector outlook.
Read from the article alone
No priced-in read yet
The company saw a significant increase in page view growth of 98.82%, suggesting increased retail or investor interest.
Read from the article alone
No priced-in read yet
The company experienced a page view growth of 96.28%, indicating higher market attention.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 81% of claims this week
Total revenues for the Medical sector are expected to rise by over 6% for the second quarter.
More positive than 56% of claims this week
Which stocks this story touches
More positive than 79% of ticker scores this week
The company has an impressive track record of beating earnings estimates over the last four quarters.
More positive than 62% of ticker scores this week
Mentioned as having significant page view growth (98.82%).
More positive than 62% of ticker scores this week
Mentioned as having significant page view growth (96.28%).
More positive than 62% of ticker scores this week
Mentioned as having significant page view growth (95.58%).
More positive than 62% of ticker scores this week
Mentioned as having significant page view growth (87.05%).
More positive than 62% of ticker scores this week
Mentioned as having significant page view growth (102.41%).
More positive than 62% of ticker scores this week
Mentioned as having significant page view growth (87.78%).
More positive than 62% of ticker scores this week
Mentioned as having a significant increase in page view growth (279.08%).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
More positive than 32% of relationship scores this week
[mutual] Both companies are described as pharma/biotech giants within the same medical sector.
—
No price for VRT right now — the quote feed didn't answer.
VRT chart →—
No price for MTZ right now — the quote feed didn't answer.
MTZ chart →—
No price for AMGN right now — the quote feed didn't answer.
AMGN chart →
